Nevin Bhardwaj

Lahey Clinic

Burlington, Massachusetts (781-744-3055)

CLINICAL TRIALS 1
CONDITIONS1
INTERVENTIONS2
SINCE2010

A Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as Second Line Therapy in Men With Castrate Resistant Prostate Cancer (CRPC)

March 2010 - June 2013

Prostatic Neoplasms

Custirsen Sodium

Isotonic, 0.9% Sodium Chloride

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Nevin Bhardwaj

Lahey Clinic

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP